PrometDobitKGVKUVEBITDividendaAkcijeKapitalizacija tržištaDugovanjeObavezeKapital društvaAAQSzaposleniROEROAROCE
H Lundbeck A/S - Akcija

H Lundbeck A/S AAQS 2024

H Lundbeck A/S AAQS

2

Тикер

LUN.CO

ISIN

DK0010287234

WKN

922351

H Lundbeck A/S ima trenutni AAQS od 2. Visok AAQS može se smatrati pozitivnim pokazateljem da se preduzeće uspešno razvija. Investitori mogu očekivati da je kompanija na dobrom putu da ostvari dobit. S druge strane, važno je posmatrati AAQS deonice H Lundbeck A/S u poređenju sa ostvarenom dobiti i drugim preduzećima iste branše. Visok AAQS nije apsolutna garancija za pozitivnu budućnost. Samo tako se može dobiti kompletna slika o performansama kompanije. Da bi se bolje procenio razvoj preduzeća, važno je posmatrati AAQS u poređenju sa drugim kompanijama iste branše. Generalno, investitori bi uvek trebali da posmatraju AAQS kompanije u kontekstu sa drugim finansijskim pokazateljima kao što su dobit, EBIT, Cash Flow i drugi, kako bi doneli obrazovane odluke o investiranju.

H Lundbeck A/S Aktienanalyse

Šta radi H Lundbeck A/S?

H Lundbeck A/S is a Danish company that was founded in 1915 by Hans Lundbeck. Since its inception, the company has focused on researching and developing medications that improve the lives of people with neuropsychiatric disorders. Lundbeck's business model is based on a clear strategy and a strong focus on the research and development of pharmaceuticals. The company has four main therapy areas: depression, anxiety disorders, Alzheimer's, and Parkinson's. Lundbeck products are sold in over 100 countries worldwide and are known for their effectiveness and high quality. Over the years, Lundbeck has also focused on developing innovative treatment methods, including research on new drugs and therapies based on neurotransmitters such as serotonin, dopamine, and norepinephrine. With the acquisition of Alder BioPharmaceuticals in 2019, Lundbeck also expanded its portfolio in the field of migraine therapy. Some of Lundbeck's most well-known products include Lexapro, Cipralex, Selincro, Abilify Maintena, and Brintellix. These medications are used in the treatment of depression, anxiety disorders, alcoholism, bipolar disorders, and migraines. In addition to selling medications, Lundbeck also provides training and support for healthcare professionals and patients. Lundbeck is also distinguished by its commitment to social engagement and works closely with nonprofit organizations to raise awareness of neuropsychiatric disorders. The company has also launched various programs to improve access to medical care in particularly affected regions. In 2020, Lundbeck exceeded 18,000 employees worldwide and had a revenue of 16.6 billion Danish kroner. Lundbeck is listed on NASDAQ OMX Copenhagen and is controlled by the Lundbeck Foundation, which holds over 70% of the company's ownership. In summary, Lundbeck is a leading company in the field of neuropsychiatric medicine and is dedicated to improving the lives of people with these serious disorders. The company has made a name for itself through its successful research and development of therapies and medications, as well as its strong focus on social engagement and corporate social responsibility. H Lundbeck A/S ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Često postavljana pitanja o H Lundbeck A/S akciji

Plansovi za štednju u akcijama nude atraktivnu mogućnost za investitore da dugoročno izgrade bogatstvo. Jedna od glavnih prednosti je takozvani efekat prosečne cene: investiranjem redovnog fiksnog iznosa u akcije ili fondove akcija, automatski se kupuju više deonica kada su cene niske i manje kada su visoke. To može dovesti do povoljnijeg prosečnog cena po deonici tokom vremena. Pored toga, plansovi za štednju u akcijama omogućuju čak i malim ulagačima pristup skupim akcijama, pošto je moguće učestvovati već sa malim iznosima. Redovno investiranje takođe podstiče disciplinovanu strategiju ulaganja i pomaže da se izbegnu emocionalne odluke, kao što su impulsivno kupovanje ili prodaja. Osim toga, investitori profitiraju od potencijalnog povećanja vrednosti akcija kao i od isplata dividendi, koje se mogu reinvestirati, što pojačava efekat kamate na kamatu i time rast investiranog kapitala.

Akcija H Lundbeck A/S je dostupna za štedne planove kod sledećih provajdera: Trade Republic

Andere Kennzahlen von H Lundbeck A/S

Naša analiza akcija za akciju H Lundbeck A/S Promet uključuje važne finansijske pokazatelje kao što su prihod, profit, P/E odnos, P/S odnos, EBIT, kao i informacije o dividendama. Takođe, razmatramo aspekte poput akcija, tržišne kapitalizacije, dugova, kapitala i obaveza kompanije H Lundbeck A/S Promet. Ako tražite detaljnije informacije o ovim temama, na našim podstranicama vam nudimo opsežne analize: